ICP Parking Lot/Vaccines: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
* Authors: Carolina Rossini
{{TOCright}}
 
= [[Vaccines/Glossary|Research Vocabulary]] =
= [[Vaccines/Glossary|Research Vocabulary]] =
=Structured Rational for the Paper=
=Structured Rational for the Paper=
# [[Vaccines/The_Argument_Framework|The Argument Framework]]
# [[Vaccines/The_Argument_Framework|The Argument Framework]]
=Study of the field=
=Study of the field=
Analysis of the field with basis on [https://cyber.law.harvard.edu/commonsbasedresearch/Field_Research_Methodology Field Research Methodology]
Analysis of the field with basis on [https://cyber.law.harvard.edu/commonsbasedresearch/Field_Research_Methodology Field Research Methodology]
# [[Overview of Economics of Intellectual Property in Vaccines]]
# [[Overview of Economics of Intellectual Property in Vaccines]]
# [[Give an overall picture of the Vaccines' sector]]
# [[Give an overall picture of the Vaccines' sector]]
Line 22: Line 17:
# [[Peer-Production Business models in Vaccines]]
# [[Peer-Production Business models in Vaccines]]
# [[Open Business models in Vaccines]]
# [[Open Business models in Vaccines]]
=[[Vaccines/Bibliography|Bibliography]]=
=[[Vaccines/Bibliography|Bibliography]]=
 
*'''American Society of Law, Medicine & Ethics, Inc., and Boston University American Journal of Law & Medicine, 2009, 35 Am. J. L. and Med.:'''
CAROL HAVE DONE LITERATURE REVIEW AND NEEDS TO INSERT IN THE WIKI
** [[Vaccines/Bibliography|Highlights]]
 
*'''Follow-On Biologics: Intellectual Property and Innovation Issues'''
'''American Society of Law, Medicine & Ethics, Inc., and Boston University American Journal of Law & Medicine, 2009, 35 Am. J. L. and Med.:'''
 
p. 247, Will HPV Vaccines Prevent Cervical Cancers Among Poor Women of Color?: Global Health Policy at the Intersection of Human Rights and Intellectual Property Law, Kevin Outterson
 
p. 253, University Contributions to the HPV Vaccine and Implications for Access to Vaccines in Developing Countries: Addressing Materials and Know-How in University Technology Transfer Policy, Sara E. Crager, Ethan Guillen, & Matt Price
 
p. 281, The Global Health Licensing Program: A New Model for Humanitarian Licensing at the University Level, Beirne Roose-Snyder & Megan K. Doyle
 
p. 311, New Vaccines for Developing Countries: Will it be Feast or Famine?, Jon Kim Andrus, MD, + Ciro de Quadros, MD, MPH, Cuauhtemoc Ruiz Matus, MD, MPH, Silvana Luciani MHSc, & Peter Hotez, MD, PhD
 
p. 323, Compulsory Licenses: A Tool to Improve Global Access to the HPV Vaccine?, Peter Maybardule & Sarah Rimmingto
 
p. 351, Clinical Preventive Services for Adolescents: Position Paper of the Society for Adolescent Medicine, Abigail English, Carol A. Ford, & John S. Santelli
 
p. 365, Human Rights In Health Equity: Cervical Cancer and HPV Vaccines, Joanna N. Erdman
 
p. 389, Potential Barriers to HPV Immunization: From Public Health to Personal Choice, Gregory D. Zimet
 
p. 401, 7040 words, ARTICLE: Overcoming Barriers and Ensuring Access to HPV Vaccines in Low-Income Countries, Vivien Davis Tsu
 
p. 415, Addressing Supply Side Barriers to Introduction of New Vaccines to the Developing World, Sean McElligott
 
'''Follow-On Biologics: Intellectual Property and Innovation Issues'''
introduces innovation policy issues pertaining to follow-on biologics. @http://www.bio.org/healthcare/followon/ and @www.biosimilars.com/CRS_FOBs.pdf  
introduces innovation policy issues pertaining to follow-on biologics. @http://www.bio.org/healthcare/followon/ and @www.biosimilars.com/CRS_FOBs.pdf  
 
*'''Emerging Health Care Issues: Follow-on Biologic Drug Competition'''
'''Emerging Health Care Issues: Follow-on Biologic Drug Competition'''
@www.ftc.gov/os/2009/06/P083901biologicsreport.pdf
@www.ftc.gov/os/2009/06/P083901biologicsreport.pdf
=[[Vaccines/Interviews|Interviews]]=
''' Completed '''
'''Recommended'''
''' Upcoming? '''
=Blogs And News=
''' News'''
''' Blogs '''
=Navigation=
=Navigation=
Back to [[Main Page]]
Back to [[Main Page]]
Back to [[Biotechnology_-_Genomic_and_Proteomics]]
Back to [[Biotechnology_-_Genomic_and_Proteomics]]

Revision as of 20:46, 5 May 2010

Research Vocabulary

Structured Rational for the Paper

  1. The Argument Framework

Study of the field

Analysis of the field with basis on Field Research Methodology

  1. Overview of Economics of Intellectual Property in Vaccines
  2. Give an overall picture of the Vaccines' sector
  3. Outputs and Products of the field: data, narratives and tools produced by the Vaccines' sector
  4. Legal tools available for and in use by the actors of Vaccines' sector: IP in Vaccines
  5. competitive advantages in Vaccines
  6. IP Profile of Biggest for-profit companies in Vaccines
  7. IP Profile of non-profit companies in Vaccines
  8. IP Profile of Universities working in Vaccines
  9. IP Profile of Associations in Vaccines
  10. Commons based cases in Vaccines
  11. Peer-Production Business models in Vaccines
  12. Open Business models in Vaccines

Bibliography

  • American Society of Law, Medicine & Ethics, Inc., and Boston University American Journal of Law & Medicine, 2009, 35 Am. J. L. and Med.:
  • Follow-On Biologics: Intellectual Property and Innovation Issues

introduces innovation policy issues pertaining to follow-on biologics. @http://www.bio.org/healthcare/followon/ and @www.biosimilars.com/CRS_FOBs.pdf

  • Emerging Health Care Issues: Follow-on Biologic Drug Competition

@www.ftc.gov/os/2009/06/P083901biologicsreport.pdf

Navigation

Back to Main Page Back to Biotechnology_-_Genomic_and_Proteomics

Retrieved from "http://cyber.harvard.edu/commonsbasedresearch/?title=ICP_Parking_Lot/Vaccines&oldid=7190"